Atlas FDA

PD-L1 IHC NIVOLUMAB PHARMDX

FDA premarket approval P150027/S004 · decided 2017-03-24

Approval details

PMA number
P150027
Supplement
S004
Supplement type
Real-Time Process
Supplement reason
Change Design/Components/Specifications/Material
Trade name
PD-L1 IHC NIVOLUMAB PHARMDX
Generic name
Immunohistochemistry assay, antibody, programmed death-ligand 1
Applicant
Dako North America, Inc.
Date received
2016-12-27
Decision date
2017-03-24
Days to decision
87 days
Decision code
APPR
Product code
PLS
Advisory committee
Pathology
Expedited review
No
Location
Carpinteria, CA
Statement
Approval for an update to DakoLink software version 4.2.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
FLEX Monoclonal Rabbitt Anti-Human Estrogen Receptor a, Clone EP1, Ready-to-Use (Link); FLEX Monoclonal Mouse Anti-Human Progesterone Receptor, Clone PgR 636, Ready-to-Use (Link) (K160922)Dako North America, Inc.2016-05-03
MONOCLONAL MOUSE ANTI-HUMAN PROGESTERONE RECEPTOR, CLONE PGR 636, READY-TO-USE (LINK) (K130861)Dako North America, Inc.2013-12-09
MONOCLONAL RABBIT ANTI-HUMAN ESTROGEN RECEPTOR (ER) A, CLONE EPI (K120663)Dako North America, Inc.2013-02-12
MONOCLONAL RABBIT ANTI HUMAN ESTROGEN RECEPTOR ALPHA ANTIBODY CLONE SP1, MODEL M3634 (K081286)Dako North America, Inc.2009-05-08